
HURA Stock Forecast & Price Target
HURA Analyst Ratings
Bulls say
TuHURA Biosciences is estimated to have a value of $636M, indicating a 12-month price objective of $10 per share. Despite the risks of negative clinical results and delays, the company's promising pipeline and innovative technologies focused on tackling resistance in cancer immunotherapy make for a positive outlook. It also helps that the company operates in a single reportable segment, allowing for a more focused and efficient approach to advancing cancer therapies.
Bears say
TuHURA Biosciences is currently facing several key risks that could negatively impact their success, including the potential for negative clinical results for their flagship product IFx-2.0, delays in obtaining regulatory approvals, and competition from other checkpoint inhibitors. However, the recent decline in stock price creates an attractive entry point for investors due to upcoming value inflection points, including preliminary results from a Phase 1b/2a trial and interim/top-line results expected in 4Q26 and 1Q27, respectively. Therefore, the financial analyst's negative outlook on TuHURA Biosciences' stock is based on the inherent risks involved in the company's pipeline and the uncertain success of their products.
This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
HURA Analyst Forecast & Price Prediction
Start investing in HURA
Order type
Buy in
Order amount
Est. shares
0 shares